




---

# Supplementary Materials: Relevance of Liquid-Liquid Phase Separation of Supersaturated Solution in Oral Absorption of Albendazole from Amorphous Solid Dispersions

Kyosuke Suzuki, Kohsaku Kawakami, Masafumi Fukiage, Michinori Oikawa, Yohei Nishida, Maki Matsuda and Takuya Fujita



**Figure S1.** TG-DTA and Polarized microscopy data for ASDs presented in this study. (a): HPMCAS ASD; (b): PVPVA ASD (3:1); (c): PVPVA ASD (4:1); (d): Eudragit ASD.

**Table S1.** Numerical data for the LLPS dissolution test (Figure 4).

Time (min)	0.2 um				0.7 um			
	Crystal	PVPVA	Eudragit	HPMCAS	Crystal	PVPVA	Eudragit	HPMCAS
0	0	0	0	0	0	0	0	0
1	0.000	0.223	1.705	0.197	0.002	2.157	2.164	1.838
3	0.015	0.303	1.923	0.454	0.045	2.432	3.082	2.317
5	0.063	0.359	2.017	0.299	0.089	2.526	3.350	2.374
10	0.087	0.382	2.082	0.339	0.107	2.839	3.778	2.477
20	0.093	0.410	2.174	0.367	0.146	2.750	3.561	2.522
30	0.105	0.433	2.221	0.369	0.144	2.303	3.074	2.501

**Table S2.** Numerical data for the rat study (Figure 6).

Time after administration (hr)	Crystalline ALZ		PVPVA ASD	
	ALZ	SD	ASD	SD
0	0	0	0	0
0.25	0.52	0.04	3.35	0.67
0.5	1.08	0.16	5.10	0.82
1	1.81	0.08	7.31	0.20
2	2.17	0.27	8.82	1.69
4	2.17	0.78	8.09	2.50
8	0.52	0.38	3.33	1.35
	HPMCAS ASD		Eudragit ASD	
	ASD	SD	ASD	SD
0	0	0	0	0
0.25	2.69	0.35	1.10	0.31
0.5	4.38	0.22	2.21	0.61
1	6.78	0.54	3.99	0.69
2	8.06	0.81	5.77	0.93
4	7.61	0.87	6.30	1.14
8	3.29	1.19	2.90	1.18

**Table S3.** Numerical data for dog study (Figure 7).

Time (hr)	Crystal		PVPVA		Eudragit	
	SD	SD	SD	SD	SD	SD
0	0.0	0.0	0.0	0.0	0.0	0.0
0.25	6.1	6.9	51.8	58.4	51.8	36.2
0.5	117.1	70.7	123.3	82.4	265.0	61.5
1	253.8	136.5	195.4	75.0	429.8	82.4
2	303.2	217.8	188.9	71.7	435.1	102.3
4	272.9	228.7	119.3	41.5	406.1	94.8
7	211.9	175.6	97.8	68.5	252.3	28.0
Time (hr)	HPMCAS		HPMCAS susp			
	SD	SD	SD	SD		
0	0.0	0.0	0.0	0.0		
0.25	127.5	105.7	271.1	58.4		
0.5	187.4	135.0	468.2	19.4		
1	267.3	158.9	538.9	133.7		
2	339.6	86.7	565.3	75.6		
4	301.6	45.6	338.1	28.6		
7	212.8	12.5	265.6	16.9		